[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitively-unimpaired\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitively-unimpaired":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,45,84],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100639031","dementia-with-lewy-bodies-clinical-symptoms-biomarkers-and-progression-100639031",false,"NCT07629349","Dementia With Lewy Bodies: Clinical Symptoms, Biomarkers and Progression","Find-DLB","Inclusion Criteria:\n\n* At least one core clinical feature of dementia with Lewy bodies such as visual hallucinations, parkinsonism, cognitive fluctuations, or probable REM sleep behaviour disorder.\n\nExclusion Criteria:\n\n* Causes of cognitive impairment other than those related to dementia or MCI. Current or pass drug use.",true,"ALL",{"count":19,"type":20},600,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to improve the detection of dementia with Lewy bodies (DLB) and its prodromal phases, as well as advancing our current understanding of biological mechanisms and therapeutic options. The data is acquired at cognitive clinics in Stockholm (Sweden) and combined with national and international data to increase statistical power, representativeness and replication of results. Participants undergo collection of clinical assessments, neuroimaging and fluid biomarkers.",[24,25,26,27],"Dementia With Lewy Bodies (DLB)","Mild Cognitive Impairment (MCI)","Cognitively Unimpaired","Other Dementias",[29,30,31],"case-control","retrospective","longitudinal","RECRUITING","2026-06-04",{"date":35,"type":36},"2026-06-05","ACTUAL",{"date":38,"type":36},"2020-01-01",{"date":40,"type":20},"2031-03-01",{"name":42,"class":43},"Karolinska Institutet","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":74,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":44},"100633617","acoustic-stimulation-during-sleep-effects-on-memory-and-p-tau217-in-mci-100633617","NCT07529015","Acoustic Stimulation During Sleep: Effects on Memory and p-tau217 in MCI","The Impact of Phase-locked Acoustic Stimulation on Sleep Structure, Memory Consolidation, and Plasma p-tau217 in Patients With Mild Cognitive Impairment","PAS-MCI","Inclusion Criteria:\n\n* Diagnosis of aMCI according to the NIA-AA criteria (Albert et al., 2011) and positive state of plasma p-tau217.\n* Diagnosis of aMCI according to the NIA-AA criteria (Albert et al., 2011) and negative state of plasma p-tau217 for aMCI negative group.\n* Cognitively unimpaired older subjects aged ≥ 65 years, Mini-mental state examination ≥28, and negative for plasma p-tau217.\n\nExclusion Criteria:\n\n* Diagnosis of dementia due to AD or any other type of dementia.\n* Presence of any diagnosed sleep disorder such as narcolepsy, severe insomnia, severe obstructive sleep apnea, or severe chronic lack of sleep.\n* Hearing problems.\n* Analphabet individuals.\n* Comorbidities such as cancer, severe depression, severe renal or hepatic insufficiency, history of seizures, and severe cardiac or respiratory failure.\n* Alcohol and substance abuse.\n* Magnetic resonance imaging (MRI) evidence of stroke, hydrocephalus, a space-occupying lesion, or any clinically relevant central nervous system disease.\n* Existence of untreated (or treated for less than 3 months prior to the screening visit) vitamin B12 or folate deficiency.\n* Presence of untreated thyroid disease.\n* Use of betablockers, antidepressants, neuroleptics, and hypnotics, within 15 days before conducting polysomnography.","60 Years",{"count":55,"type":20},114,"INTERVENTIONAL",[58],"NA","The goal of this clinical trial is to determine whether acoustic stimulation during sleep can enhance slow-wave sleep (SWS), improve cognitive function, and reduce AD-related pathology in individuals with mild cognitive impairment (MCI), compared with cognitively healthy participants.\n\nThe main questions it aims to answer are:\n\n1. Does acoustic stimulation increase SWS (e.g., slow oscillation and sleep spindle activity) in individuals with MCI?\n2. Does enhancing SWS lead to improvements in memory and cognitive performance?\n3. Does acoustic stimulation influence plasma p-tau217 levels as a marker of underlying Alzheimer's disease pathology? Researchers will compare participants receiving acoustic stimulation during sleep with those not receiving stimulation to evaluate its effects on sleep architecture, cognition, and plasma biomarkers.\n\nParticipants will:\n\n* Undergo sleep recordings to assess sleep architecture, including SWS, slow oscillations, and sleep spindles\n* Receive acoustic stimulation during sleep across multiple nights\n* Complete cognitive assessments, particularly memory-related tasks\n* Provide blood samples to measure plasma p-tau217 levels\n* Provide clinical and demographic information for analysis",[61,62,26],"Alzheimer's Disease (AD)","Mild Cognitive Impairment (MCI) Amnestic",[64,65,66,67,68,69,70,71,72,73],"Alzheimer's disease","acoustic stimulation","declarative memory","amnestic mild cognitive impairment","sleep spindle","episodic memory","sleep EEG","slow-wave sleep","p-tau217","slow oscillation","NOT_YET_RECRUITING","2026-04-07",{"date":77,"type":36},"2026-04-14",{"date":79,"type":20},"2026-04",{"date":81,"type":20},"2028-12",{"name":83,"class":43},"Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":16,"sex":17,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":96,"conditions":97,"keywords":106,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":125},"100316694","comprehensive-assessment-of-neurodegeneration-and-dementia-100316694","NCT03402919","Comprehensive Assessment of Neurodegeneration and Dementia","The Comprehensive Assessment of Neurodegeneration and Dementia Study","COMPASS-ND","Inclusion Criteria:\n\n* Has subjective or objective cognitive impairment\n* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver\u002Ffamily member)\n* Sufficient proficiency in English or French to undertake self report and neuropsychological testing\n* Geographic accessibility to the study site\n* Must have a study partner who can participate as required in the protocol (provide corroborative information)\n* Up to 12 years of education\n* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment\n\nExclusion Criteria:\n\n* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses\n* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures\n* Symptomatic stroke within the previous year\n* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure","50 Years","90 Years",{"count":95,"type":20},1573,"This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are\u002Fwill be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.",[98,25,99,100,101,102,103,104,26,105],"Dementia","Subjective Cognitive Impairment","Parkinson's Disease (PD)","Lewy Body Disease(LBD)","Mixed Dementia","Frontotemporal Dementia (FTD)","Alzheimer Disease (AD)","Subjective Cognitive Decline (SCD)",[107,98,108,109,110,111,112,113,114,115],"Observational","Alzheimer's Disease","Parkinson's Disease","Biosample","Genetics","Neuropsychological","MRI","Microbiome","Plasma","2026-01-15",{"date":118,"type":36},"2026-01-20",{"date":120,"type":36},"2016-06",{"date":122,"type":20},"2029-12",{"name":124,"class":43},"McGill University",19]